Artificial intelligence in Parkinson's disease: Early detection and diagnostic advancements

被引:6
|
作者
Reddy, Aananya [1 ,2 ]
Reddy, Ruhananhad P. [1 ,2 ]
Roghani, Aryan Kia [1 ,3 ]
Garcia, Ricardo Isaiah [1 ]
Khemka, Sachi [1 ]
Pattoor, Vasanthkumar [1 ,5 ]
Jacob, Michael [1 ,4 ]
Reddy, P. Hemachandra [1 ,6 ,7 ,8 ,9 ]
Sehar, Ujala [1 ]
机构
[1] Texas Tech Univ, Hlth Sci Ctr, Dept Internal Med, Lubbock, TX 79430 USA
[2] Lubbock High Sch, Lubbock, TX 79401 USA
[3] Frenship High Sch, Lubbock, TX 79382 USA
[4] Univ Texas San Antonio, Dept Biol, San Antonio, TX 78249 USA
[5] Univ S Florida, Tampa, FL 33620 USA
[6] Texas Tech Univ, Coll Human Med, Hlth Sci Ctr, Nutr Sci Dept, Lubbock, TX 79430 USA
[7] Texas Tech Univ, Hlth Sci Ctr, Publ Hlth Dept, Grad Sch Biomed Sci, Lubbock, TX 79430 USA
[8] Texas Tech Univ, Hlth Sci Ctr, Sch Hlth Profess, Dept pf Speech Language & Hearing Serv, Lubbock, TX 79430 USA
[9] Texas Tech Univ, Hlth Sci Ctr, Dept Pharmacol & Neurosci, Lubbock, TX 79430 USA
基金
美国国家卫生研究院;
关键词
Parkinson's disease; Early detectable biomarkers; Therapeutic strategies; Artificial intelligence; Machine learning tools; SOCIOECONOMIC-STATUS; ETHNIC VARIATION; BIOMARKERS; PROGRESSION; POPULATION; PREVALENCE; CONSENT; IMPACT;
D O I
10.1016/j.arr.2024.102410
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Parkinson's disease (PD) is the second most common neurodegenerative disorder, globally affecting men and women at an exponentially growing rate, with currently no cure. Disease progression starts when dopaminergic neurons begin to die. In PD, the loss of neurotransmitter, dopamine is responsible for the overall communication of neural cells throughout the body. Clinical symptoms of PD are slowness of movement, involuntary muscular contractions, speech & writing changes, lessened automatic movement, and chronic tremors in the body. PD occurs in both familial and sporadic forms and modifiable and non-modifiable risk factors and socioeconomic conditions cause PD. Early detectable diagnostics and treatments have been developed in the last several decades. However, we still do not have precise early detectable biomarkers and therapeutic agents/drugs that prevent and/or delay the disease process. Recently, artificial intelligence (AI) science and machine learning tools have been promising in identifying early detectable markers with a greater rate of accuracy compared to past forms of treatment and diagnostic processes. Artificial intelligence refers to the intelligence exhibited by machines or software, distinct from the intelligence observed in humans that is based on neural networks in a form and can be used to diagnose the longevity and disease severity of disease. The term Machine Learning or Neural Networks is a blanket term used to identify an emerging technology that is created to work in the way of a "human brain" using many intertwined neurons to achieve the same level of raw intelligence as that of a brain. These processes have been used for neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease, to assess the severity of the patient's condition. In the current article, we discuss the prevalence and incidence of PD, and currently available diagnostic biomarkers and therapeutic strategies. We also highlighted
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Artificial intelligence-enabled detection and assessment of Parkinson’s disease using nocturnal breathing signals
    Yuzhe Yang
    Yuan Yuan
    Guo Zhang
    Hao Wang
    Ying-Cong Chen
    Yingcheng Liu
    Christopher G. Tarolli
    Daniel Crepeau
    Jan Bukartyk
    Mithri R. Junna
    Aleksandar Videnovic
    Terry D. Ellis
    Melissa C. Lipford
    Ray Dorsey
    Dina Katabi
    Nature Medicine, 2022, 28 : 2207 - 2215
  • [22] Artificial intelligence applications and robotic systems in Parkinson's disease (Review)
    Perju-Dumbrava, Lacramioara
    Barsan, Maria
    Leucuta, Daniel
    Popa, Luminita C.
    Pop, Cristina
    Tohanean, Nicoleta
    Popa, Stefan L.
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2022, 23 (02)
  • [23] Artificial Intelligence and Visual Analysis of Movements in Parkinson's disease (PD)
    Okelberry, T.
    Beisar, H.
    Horev, S.
    Pinchuk, E.
    Lyons, K.
    Pahwa, R.
    MOVEMENT DISORDERS, 2024, 39 : S563 - S563
  • [24] The use of artificial intelligence-based chatbot in Parkinson's disease
    Oyama, G.
    Ogawa, M.
    Morito, K.
    Kobayashi, M.
    Yamada, Y.
    Shinkawa, K.
    Kamo, H.
    Hatano, T.
    Hattori, N.
    MOVEMENT DISORDERS, 2022, 37 : S199 - S200
  • [25] Drug repositioning for Parkinson's disease: An emphasis on artificial intelligence approaches
    Karimi-Sani, Iman
    Sharifi, Mehrdad
    Abolpour, Nahid
    Lotfi, Mehrzad
    Atapour, Amir
    Takhshid, Mohammad-Ali
    Sahebkar, Amirhossein
    AGEING RESEARCH REVIEWS, 2025, 104
  • [26] Artificial Intelligence Diagnosis of Parkinson's Disease From MRI Scans
    Reddy, Shreya
    Giri, Dinesh
    Patel, Rakesh
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (04)
  • [27] Application of artificial intelligence to Parkinson's disease (PD) pharmacological therapy
    Honczarenko, K
    Honczarenko, J
    Jardzioch, A
    Sieredzinski, J
    MOVEMENT DISORDERS, 2002, 17 : S85 - S85
  • [28] Artificial Intelligence Model for Parkinson Disease Detection Using Machine Learning Algorithms
    Sunil Yadav
    Munindra Kumar Singh
    Saurabh Pal
    Biomedical Materials & Devices, 2023, 1 (2): : 899 - 911
  • [29] An insight on recent advancements and future perspectives in detection techniques of Parkinson's disease
    Sankineni, Snehith
    Saraswat, Aanchal
    Suchetha, M.
    Aakur, Sathyanarayanan N.
    Sehastrajit, S.
    Dhas, D. Edwin
    EVOLUTIONARY INTELLIGENCE, 2024, 17 (03) : 1715 - 1731
  • [30] Potential Ocular Biomarkers for Early Detection of Alzheimer's Disease and Their Roles in Artificial Intelligence Studies
    Chaitanuwong, Pareena
    Singhanetr, Panisa
    Chainakul, Methaphon
    Arjkongharn, Niracha
    Ruamviboonsuk, Paisan
    Grzybowski, Andrzej
    NEUROLOGY AND THERAPY, 2023, 12 (05) : 1517 - 1532